When was EvolveMol founded?

EvolveMol was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is EvolveMol located?

EvolveMol is headquartered in Berkeley, United States.

Who is the current CEO of EvolveMol?

Zachary Apte of EvolveMol. They have also founded 1 company.

How many employees does EvolveMol have?

As of Jul 01, 2024, the latest employee count at EvolveMol is 1.

Is EvolveMol a funded company?

EvolveMol is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 2011.

When was the latest funding round of EvolveMol?

EvolveMol's latest funding was a $***** Seed round on 2015, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $803M in funding in 2026 to date.

Where does EvolveMol rank among its competitors?

EvolveMol ranks 1556th amongst 1957 active competitors, of which 452 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of EvolveMol?

EvolveMol's top competitors include Synthego, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

EvolveMol - 2026 Company Profile, Team, Funding & Competitors

Company Details

EvolveMol is focussed on developing microorganisms to produce small molecules for the bioenergy and pharmaceutical industries. It has developed a patent-pending process that combines the mathematics of computer science and full-fledged evolution to produce microorganisms. It claims that its platform is simple and can produce fuel or complex pharmaceuticals easily.

Website: evolvemol.com
Social
Email ID: *****@evolvemol.com

Key Metrics

Founded Year

2011

Location

Berkeley, United States

Stage

Deadpooled

Latest Funding Round

Seed, 2015, $*****

Investors

DOE & 2 more

Ranked

1556^th among 1957 active competitors

Employee Count

1 as on Jul 01, 2024

Similar Companies

Synthego & 2666 more

View EvolveMol's full profile

EvolveMol has raised funding over 4 rounds. Its first funding round was on Jul 2011. Its latest funding round was a Seed round on 2015 for $*****. 1 investor participated in its latest round. EvolveMol has 3 institutional investors.

Here is the list of recent funding rounds of EvolveMol:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2015	2296	Seed	8308	2221	1356	4872
Apr 09, 2013	2550879	Grant (prize money)	3394613	2355308	9624461	DOE
Feb 20, 2012	2092898	Grant (prize money)	1601008	4431749	5716938	DOE

Access funding benchmarks and valuations. Sign up today!

View details of EvolveMol's funding rounds and investors

The founders of EvolveMol is Zachary Apte. Zachary Apte is the CEO of EvolveMol.

Here are the details of EvolveMol's key team members:

Zachary Apte: Founder & CEO of EvolveMol and founder of 1 other company.

View details of EvolveMol's Founder profiles and Board Members

EvolveMol's employee count trend

EvolveMol has 1 employees as of Jul 24. Here is EvolveMol's employee count trend over the years:

Uncover EvolveMol's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EvolveMol include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of EvolveMol, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Sino Biopharmaceutical, Orbimed & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Verition Fund Management ... & 14 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, Polaris Partners & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
1556th	EvolveMol 2011, Berkeley (United States), Deadpooled	Developing microoragnisms to produce small molecules for bioenergy & pharmaceutical industries	-	DOE, QB3 & 1 others	23/100